Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result
Brain and CNS tumors
Liposomal curcumin (LC) + RT/TMZ hits RP2D 350mg/m² with early survival signal in newly diagnosed IDH-wt GBM
Liposomal curcumin (LC) is an IV nano/liposomal curcumin formulation intended to improve curcumin exposure and modulate inflammatory/oxidative and oncogenic signaling (including kynurenine-pathway biology) alongside…
NCT05768919 - Trial result
Brain and CNS tumors
Lucicebtide/ST101 (C/EBPβ Antagonist) Shows Early Survival Signal in GBM
Lucicebtide (ST101) is a first-in-class peptide antagonist of C/EBPβ designed to suppress the mesenchymal GBM program and reprogram immunosuppressive tumor-associated myeloid cells. In a Phase 2 window-of-opportunity…
NCT04478279 - Trial result
Brain and CNS tumors
GammaTile Cs-131 Brachytherapy + Stupp Cuts Rapid Early Progression to 6% in GBM
GammaTile is a cesium-131 collagen-tile brachytherapy platform implanted at resection to deliver immediate local radiation, then followed by abbreviated EBRT with concurrent/adjuvant temozolomide in the prospective…
NCT05342883 - Trial result Spotlight
Ovarian cancer
Azenosertib (WEE1 inhibitor) + weekly paclitaxel delivers 39% ORR in platinum-resistant ovarian cancer
Azenosertib (ZN-c3) is an oral, selective WEE1 kinase inhibitor designed to exploit replication stress and impair DNA-damage checkpoint control; in the MUIR Phase 1b open-label dose-escalation trial (NCT04516447), it…
NCT04516447 - Trial result Spotlight
Ovarian cancer
Relacorilant (glucocorticoid receptor antagonist) + nab-paclitaxel extends OS by 4.1 months in platinum-resistant ovarian cancer
Relacorilant is a first-in-class, selective glucocorticoid receptor (GR) antagonist intended to counter GR-mediated chemotherapy resistance, and was combined with weekly nab-paclitaxel in the Phase 3 ROSELLA trial…
NCT05257408 - Trial result Spotlight
Ovarian cancer
TUB-040 (NaPi2b Exatecan ADC) Delivers 61% cORR in Platinum-Resistant Ovarian Cancer
TUB-040 is a NaPi2b-targeted antibody–drug conjugate with a DAR8 exatecan topoisomerase I payload via a cleavable P5 linker, evaluated as every-3-week monotherapy in biomarker-unselected platinum-resistant ovarian…
NCT06303505 - Trial result
Ovarian cancer
SBS5 (clock-like) mutational signature flags longer PFS after cisplatin HIPEC in EOC
In a single-center WES biomarker analysis of patients with primary or recurrent epithelial ovarian cancer (EOC) treated with cisplatin HIPEC during optimal cytoreductive surgery (cisplatin 75mg/m², 60 min, 42°C;…
NCT01970722 - Trial result
Ovarian cancer
Delayed interval debulking (6-cycle NAC) shows no DFS gain vs standard 3-cycle timing in CHRONO ovarian cancer
CHRONO (NCT03579394) tested whether delaying complete cytoreductive surgery after neoadjuvant platinum-taxane chemotherapy improves outcomes in FIGO stage IIIB–IVA high-grade epithelial ovarian cancer that was deemed…
NCT03579394 - Trial result
Ovarian cancer
Mirvetuximab soravtansine (FRα ADC) + carboplatin fails to improve PFS vs standard platinum doublets in FRα-high recurrent ovarian cancer
Mirvetuximab soravtansine (MIRV) is an FRα-targeted antibody–drug conjugate delivering the maytansinoid payload DM4; in MIROVA/AGO-OVAR 2.34 (Phase II; NCT04274426), platinum-eligible recurrent ovarian cancer with…
NCT04274426 - Trial result
Ovarian cancer
Sacituzumab govitecan (TROP2 ADC delivering SN-38) posts 35% ORR and 8.0‑mo mPFS in platinum‑resistant ovarian cancer
Sacituzumab govitecan (SG) is a TROP2-directed antibody–drug conjugate that delivers SN-38 (irinotecan’s active metabolite) to TROP2-expressing tumor cells; in this single-institution, open-label Phase II study…
NCT06028932 - Trial result
Ovarian cancer
ETX-19477 (oral PARG inhibitor) posts 29% PR rate in heavily pretreated BRCA-mut HGSOC
ETX-19477 is an oral, potent, selective poly(ADP-ribose) glycohydrolase (PARG) inhibitor designed to exploit replication-fork DNA repair vulnerabilities (mechanistically distinct from PARP inhibitors). In the…
NCT06395519 - Trial result
Ovarian cancer
BI-1808 (TNFR2 IgG1 mAb; Treg-depleting) + pembrolizumab delivers 24% ORR in heavily pretreated ovarian cancer
BI-1808 is an anti-TNFR2 IgG1 monoclonal antibody designed to block TNF-α/TNFR2 signaling and, via FcγR engagement, deplete tumor Tregs and reprogram myeloid cells—mechanistically complementary to PD-1 blockade with…
NCT04752826 - Trial result
Ovarian cancer
YL205 (NaPi2b-targeted topo1 ADC) posts 46.5% ORR in heavily pretreated ovarian cancer
YL205 is a NaPi2b-directed antibody–drug conjugate delivering a topoisomerase I inhibitor payload (TMALIN platform) evaluated as monotherapy in the first-in-human, multicenter, open-label Phase I/II YL205-CN-101-01…
NCT06459973 - Trial result Spotlight
Prostate cancer
CAN-2409 (HSV‑tk adenoviral gene therapy) + valacyclovir improves DFS when added to curative EBRT in localized prostate cancer
Aglatimagene besadenovec (CAN-2409) is an intraprostatic, replication-defective adenoviral vector expressing HSV‑thymidine kinase; with valacyclovir it drives tumor cell kill and immunogenic cell death, and was…
NCT01436968 - Trial result Spotlight
Prostate cancer
Apalutamide (androgen receptor inhibitor) + perioperative ADT improves 5-year MFS in high-risk localized/locally advanced prostate cancer undergoing prostatectomy
Apalutamide is an oral androgen receptor pathway inhibitor added to standard androgen-deprivation therapy (ADT) to intensify perioperative systemic control around radical prostatectomy. In the Phase 3 double-blind…
NCT03767244 - Trial result Spotlight
Prostate cancer
Talazoparib (PARP inhibitor) + enzalutamide (AR inhibitor) boosts 3-year PFS to 77% in HRR-altered mHSPC
Talazoparib is an oral PARP1/2 inhibitor combined with enzalutamide, a potent androgen-receptor signaling inhibitor, on top of ADT in TALAPRO-3 (Phase 3, double-blind; NCT04821622) for metastatic androgen pathway…
NCT04821622 - Trial result Spotlight
Prostate cancer
ABBV-969 (PSMA/STEAP1 dual-targeting Top1i ADC) drives 45% ORR and 67% PSA50 in heavily pretreated mCRPC
ABBV-969 is a first-in-class dual-targeting antibody–drug conjugate (ADC) against PSMA and STEAP1 delivering a topoisomerase-1 inhibitor payload, evaluated as Q3W monotherapy in the Phase 1 FIH dose-escalation study…
NCT06318273 - Trial result
Prostate cancer
COMPPARE Proton Therapy vs IMRT (photon) Shows No 2-Year Bowel QOL Advantage in Localized Prostate Cancer
COMPPARE (NCT03561220) is a large prospective, non-randomized comparative effectiveness study testing proton therapy (PT; particle RT with Bragg-peak dose deposition) versus photon IMRT in treatment-naïve localized…
NCT03561220 - Trial result
Prostate cancer
Apalutamide (AR antagonist) + ADT periop boosts pCR/MRD and improves 5-year MFS after prostatectomy in high-risk localized/locally advanced disease
Apalutamide (APA), an androgen receptor inhibitor, was added to androgen deprivation therapy (ADT) perioperatively (6 months neoadjuvant, then 6 months adjuvant) around radical prostatectomy (RP) in the double-blind…
NCT03767244 - Trial result
Prostate cancer
Talazoparib (PARP inhibitor) + enzalutamide (AR inhibitor) halves rPFS risk in HRR-altered mCSPC
Talazoparib is an oral PARP inhibitor that exploits homologous recombination repair (HRR) deficiency, and enzalutamide is an androgen-receptor signaling inhibitor; in the double-blind Phase 3 TALAPRO-3 trial…
NCT04821622 - Trial result
Prostate cancer
MMAI digital pathology AI biomarker predicts abiraterone benefit (CYP17 inhibition) in very high-risk M0 prostate cancer
MMAI is a locked multimodal AI model built from digital pathology plus PSA, T-stage, and age, tested post hoc across two sequential randomized STAMPEDE Phase 3 abiraterone comparisons in clinically very high-risk,…
NCT00268476 - Trial result
Prostate cancer
Enzalutamide + ribociclib (CDK4/6) misses PSA50 bar but extends rPFS/OS in RB+ mCRPC
Enzalutamide is an androgen receptor (AR) inhibitor and ribociclib is an oral CDK4/6 inhibitor intended to “re-awaken” RB tumor suppressor function by preventing RB hyperphosphorylation; RiboX (Phase Ib/II;…
NCT02555189 - Trial result
Prostate cancer
Enzalutamide-era mCRPC: ctDNA AR enhancer/AR copy gains sharpen rPFS risk stratification (Alliance A031201)
A031201 randomized chemotherapy-naïve mCRPC patients to the androgen receptor (AR) pathway inhibitor enzalutamide ± abiraterone acetate/prednisone (n=776 with baseline ctDNA profiled by the AR-ctDETECT assay;…
NCT01949337 - Trial result
Prostate cancer
ST-DoxPCa (AI “virtual spatial transcriptomics”) identifies an OS-benefiting subgroup for adjuvant docetaxel in high-risk localized prostate cancer
ST-DoxPCa is an AI/computational pathology biomarker built from routine H&E biopsies using a Vision Transformer to infer spot-level expression for a prostate gene panel (distilled to a locked 26-gene signature;…
- Trial result
Prostate cancer
Rucaparib (PARP inhibitor) extends rPFS in BRCA-mutant mCRPC regardless of when prior ARPI was used
Rucaparib is an oral PARP inhibitor evaluated in the Phase 3 TRITON3 trial (NCT02975934) versus physician’s choice of docetaxel or an ARPI (abiraterone/enzalutamide) in BRCA1/2-mutated mCRPC after progression on 1…
NCT02975934 - Trial result
Prostate cancer
Xaluritamig (STEAP1×CD3 T-cell engager) + abiraterone posts 58% PSA50 and 43% ORR in chemo‑naïve mCRPC
Xaluritamig (xalu) is a STEAP1×CD3 bispecific T-cell engager combined with abiraterone acetate + predniso(lo)ne in an open-label Phase 1 dose exploration/expansion study (NCT04221542) in taxane-naïve mCRPC with ≤2…
NCT04221542 - Trial result
Prostate cancer
Cabazitaxel/carbo + nivolumab/ipilimumab (PD-1/CTLA-4) hits 78% 6-mo rPFS in metastatic NEPC/AVPC
CHAMP (NCT04709276) is a multicenter, single-arm Phase 2 trial testing cabazitaxel (taxane microtubule inhibitor) + carboplatin (platinum) with dual checkpoint blockade nivolumab (PD-1) and ipilimumab (CTLA-4),…
NCT04709276 - Trial result
Prostate cancer
Enzalutamide + PARP inhibitor rucaparib adds PSA drops—but no clear rPFS/OS win in all-comer 1L mCRPC (CASPAR)
Alliance A031902 (CASPAR; NCT04455750) tested enzalutamide (androgen receptor inhibitor) plus rucaparib (PARP inhibitor) vs enzalutamide + placebo as first-line therapy for metastatic castration-resistant prostate…
NCT04455750 - Trial result
Prostate cancer
Fuzuloparib (PARP inhibitor) + abiraterone extends rPFS in 1L mCRPC, with biggest lift in DRD+
FUZUPRO (NCT04691804) is an international, randomized, double-blind Phase 3 trial testing fuzuloparib (oral PARP inhibitor) 150mg BID plus abiraterone acetate/prednisone (AA-P) vs placebo + AA-P as first-line therapy…
NCT04691804 - Trial result
Prostate cancer
A-DREAM (Alliance A032101): Intermittent ADT+ARPI interruption delivers 41% 18‑mo treatment-free eugonadal recovery in mHSPC
A-DREAM is a single-arm Phase 2 de-escalation strategy testing interruption of testosterone suppression (ADT/TS) plus an androgen receptor pathway inhibitor (ARPI) after an “exceptional response” (PSA<0.2ng/mL on…
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.